Evaxion Biotech AS (EVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.27M
Last updated: Nov 17, 2026 at 11:01 AM ET
Evaxion Biotech AS (EVAX) Earnings: Report Dates and Results
Evaxion Biotech AS (EVAX) is confirmed to report earnings on Nov 19, 2026, before the open. In the quarter ended Jun 30, 2026, Evaxion Biotech AS reported EPS of -$0.50. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EVAX has a confirmed report date of Nov 19, 2026, before the open.
EVAX Earnings Call
The latest EVAX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 23 quarters below that had an estimate, EVAX beat 13, missed 7 and matched 3. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 200.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.50 | -$0.01 | -$0.01 - -$0.01 | N/A | N/A | N/A | 1 | 0 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.01 | -$0.01 | -$0.45 - -$0.01 | 0.00% | In line | N/A | 2 | 1 up, 0 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | 0.00% | In line | N/A | 1 | 1 up, 1 down | Mar 5, 2026 | $22040 |
| Sep 30, 2025 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +200.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 6, 2025 | $7.49M |
| Jun 30, 2025 | -$1.00 | -$0.58 | -$0.66 - -$0.50 | -72.41% | Miss | N/A | 2 | 0 up, 2 down | Aug 14, 2025 | $37000 |
| Mar 31, 2025 | -$0.50 | -$0.70 | -$0.76 - -$0.65 | +28.57% | Beat | -266.7% | 2 | 0 up, 1 down | May 27, 2025 | $122000 |
| Dec 31, 2024 | -$0.07 | -$0.15 | -$0.69 - -$0.03 | +53.33% | Beat | N/A | 3 | 1 up, 0 down | Mar 26, 2025 | $122000 |
| Sep 30, 2024 | -$0.20 | -$0.60 | -$0.75 - -$0.04 | +66.67% | Beat | N/A | 3 | 1 up, 0 down | Oct 31, 2024 | $3.02M |
| Jun 30, 2024 | -$6.00 | -$3.50 | -$3.50 - -$0.40 | -71.43% | Miss | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | $154000 |
| Mar 31, 2024 | $0.30 | -$0.56 | -$0.99 - -$0.12 | +153.57% | Beat | N/A | 2 | 0 up, 0 down | May 28, 2024 | $50881 |
| Dec 31, 2023 | -$8.00 | -$8.00 | N/A | 0.00% | In line | N/A | 2 | 0 up, 0 down | Mar 27, 2024 | $73000 |
| Sep 30, 2023 | -$10.50 | -$9.75 | N/A | -7.69% | Miss | N/A | N/A | 0 up, 0 down | Dec 19, 2023 | N/A |
| Jun 30, 2023 | -$10.50 | -$10.75 | -$11.00 - -$10.50 | +2.33% | Beat | N/A | 2 | 0 up, 0 down | Aug 18, 2023 | N/A |
| Mar 31, 2023 | -$14.50 | -$13.17 | -$13.50 - -$10.50 | -10.10% | Miss | N/A | 2 | 0 up, 0 down | Apr 27, 2023 | N/A |
| Dec 31, 2022 | -$2.90 | -$2.63 | N/A | -10.27% | Miss | N/A | N/A | 0 up, 0 down | Dec 31, 2022 | N/A |
| Nov 14, 2022 | -$12.00 | -$17.00 | N/A | +29.41% | Beat | N/A | N/A | N/A | Nov 14, 2022 | N/A |
| Sep 30, 2022 | -$12.00 | -$13.33 | -$17.00 - -$11.00 | +9.98% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$10.00 | -$15.00 | -$16.50 - -$14.00 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Aug 10, 2022 | N/A |
| Mar 31, 2022 | -$0.25 | -$0.33 | -$0.39 - -$0.24 | +24.24% | Beat | N/A | 3 | 0 up, 0 down | May 11, 2022 | N/A |
| Dec 31, 2021 | -$19.50 | -$15.00 | -$15.00 - -$14.00 | -30.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 22, 2022 | N/A |
| Sep 30, 2021 | -$13.50 | -$17.25 | -$18.00 - -$16.00 | +21.74% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2021 | N/A |
| Jun 30, 2021 | -$18.00 | -$14.75 | -$15.00 - -$14.50 | -22.03% | Miss | N/A | 3 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$11.50 | -$16.50 | -$16.50 - -$13.50 | +30.30% | Beat | N/A | 2 | N/A | Apr 6, 2021 | N/A |
| Dec 31, 2020 | -$0.19 | -$0.25 | -$0.25 - -$0.25 | +24.00% | Beat | N/A | 1 | N/A | Jan 25, 2021 | N/A |
| Sep 30, 2020 | -$9.90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$7.58 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 5, 2020 | N/A |
| Mar 31, 2020 | -$6.46 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 5, 2020 | N/A |
| Dec 31, 2019 | -$7.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.50, after -$5.97 the year before. It was -$11.52 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.50 | N/A |
| Dec 31, 2024 | -$5.97 | N/A |
| Dec 31, 2023 | -$43.50 | N/A |
| Dec 31, 2022 | -$25.15 | N/A |
| Dec 31, 2021 | -$62.50 | N/A |
| Dec 31, 2020 | -$0.19 | N/A |
| Dec 31, 2019 | -$27.60 | N/A |
| Dec 31, 2018 | -$11.52 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,700 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,723 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,514 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,603 | 8 | |
| 2025Q3 | Sep 30, 2025 | 2,892 | 6 | |
| 2025Q2 | Jun 30, 2025 | 2,649 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,181 | 5 | |
| 2024Q2 | Jun 30, 2024 | 3,600 | 8 |
2026Q2 Earnings Call
Opening remarks
Helen Tayton-Martin Chief Executive Officer Thank you. I'm Helen Tayton-Martin. I'm the Chief Executive of Evaxion, and we're delighted today to be presenting our Q2 business update. I'm joined today on the call by Birgitte Røno, our Chief Scientific Officer and Chief Operating Officer, who will provide an overview of our updates in our R&D pipeline and AI-Immunology platform. Then I'll hand over to Thomas Schmidt, who will talk through our Q2 financial results before we bring it back to conclusions and Q&A. So first, of course, we may make forward-looking statements, and the audience is advised to look at our recently filed SEC documents. And now I'll kick off the discussion. So really, Q2 has been marked by a series of achievements in our four core areas or four core platforms for the company. First of all, just focusing on business development. As previously and ongoing through the course of this year, there are many discussions we are having with partners regarding the Evaxion programs and pipeline. We've had a new stream of very encouraging new data, which continues to come through and continuously validate the AI-Immunology platform, which really feeds into those various conversations, and we'll touch on some of those today. In particular, in our R&D area, we have been very pleased to be accepted to present further updates on our EVX-01 program, our personalized neoantigen cancer vaccine in advanced melanoma patients. It was a great day for the field yesterday to see the positive Phase III results from the similar Moderna and Merck program in personalized cancer vaccine in melanoma. It will be great for us and the field to talk more about that as we head into ESMO and provide an update on our own data there. Elsewhere, we have been working to refocus and expand the pipeline, leveraging our learnings with our EVX-03 and EVX-01 platforms into a new program, which we call EVX-05 in glioblastoma, where we are further leveraging the endogenous retrovirus elements that we have been able to identify—highly conserved ERV antigens for glioblastoma—building on what we have done in our EVX-04 program using a similar approach to use AI-Immunology to find highly conserved ERV antigens in AML. We presented new preclinical data on that earlier this year at the European Hematology Association Annual Conference. We've also updated our infectious disease portfolio on our EVX-V1 CMV program at the recent Herpes Simplex Conference last month. More broadly, on AI-Immunology, the platform itself, we were really delighted to see that recognized in the Galien UK Award, a second Galien award we have had for the technology in the last 12 months.
Frequently Asked Questions About EVAX
When is Evaxion Biotech AS's next earnings date?
Evaxion Biotech AS's next earnings report is confirmed for Nov 19, 2026, before the open.
What EPS do analysts expect from EVAX next quarter?
The consensus EPS estimate for Evaxion Biotech AS for the quarter ended Sep 30, 2026 is -$0.01 from 1 analyst, with estimates from -$0.01 to -$0.01.
How often does EVAX beat earnings estimates?
Evaxion Biotech AS beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +25.59%.
Does EVAX report before or after the market opens?
Evaxion Biotech AS is confirmed to report on Nov 19, 2026, before the market opens.
EVAX pages: Overview, Earnings, Forecast, Valuation, Competitors